dn 108 has been researched along with irinotecan in 1 studies
| Studies (dn 108) | Trials (dn 108) | Recent Studies (post-2010) (dn 108) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 7 | 0 | 1 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | dn 108 (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukumoto, H; Kanzawa, F; Koh, Y; Koizumi, F; Nakamura, T; Nishio, K; Saijo, N; Tatsumi, Y; Yoshioka, T | 1 |
1 other study(ies) available for dn 108 and irinotecan
| Article | Year |
|---|---|
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Thiazoles; Thiazolidinediones; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |